Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRONG Trial: Abemaciclib, Endocrine Therapy, and SRS in HR+/HER2- Breast Cancer Brain Metastases
NCT04923542Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2021
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in breast cancer with brain metastases (BCBM) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Intracranial Progression Free Survival at 12 months. Started Nov 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer with brain metastases (BCBM)
Beyond the preview
Go deeper on NCT04923542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923542.